Business

Synta stock rises on promising test of breast cancer drug

A radiologist views images from mammography, used to detect breast cancer.
A radiologist views images from mammography, used to detect breast cancer.Wichita Times-Record-News/AP

This is a summary. To read the whole story subscribe to BostonGlobe.com

Synta Pharmaceuticals Corp. gained the most in four-plus years after a small trial of its drug for breast cancer met the goals, warranting expansion of the study. Ganetespib helped enough patients see a reduction in tumors to move to a second stage of the trial. The drug was tested in patients with newly diagnosed HER2-positive or triple-negative breast cancer. “The results easily surpassed the [study] expansion criteria,” wrote analyst George Zavoico, at MLV & Co. The drug also is being tested for lung and other cancers.

Full story for BostonGlobe.com subscribers.

Get the full story with unlimited access to BostonGlobe.com.

Just 99 cents for four weeks.

Share